Danaher supplies life-sciences and diagnostics technologies through a portfolio of specialized operating companies. Its businesses provide bioprocessing equipment and consumables, genomics and laboratory tools, and clinical diagnostic instruments and tests. Customers include drug developers, researchers, hospitals, and laboratories; recurring consumables, installed equipment bases, and services are central to its model.
Danaher Corp. (DHR) has a MarketKingdoms composite score of 65.1 (B), an B-range rating. It ranks 809th of 1,866 covered companies, 35th of 78 in Healthcare (sector average 64.5) and 12th of 13 in Diagnostics & Research. Scores as of 2026-10-25.
Its strongest lenses are Industry opportunity at 90 (Healthcare average 81) and Stock selection at 75 (Healthcare average 79). Its weakest lenses are Price (valuation) at 33 (sector average 50) and Expansion (growth) at 47 (sector average 50).
| Lens | Type | DHR | Healthcare average | Diagnostics & Research average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 90 | 81 | 90 | 95th |
| Stock selection | Research signal | 75 | 79 | 83 | 24th |
| KPI momentum | Research signal | 72 | 78 | 85 | 31st |
| Catalyst watch | Research signal | 73 | 74 | 77 | 41st |
| Price (valuation) | Fundamental lens | 33 | 50 | 32 | 31st |
| Expansion (growth) | Fundamental lens | 47 | 50 | 52 | 51st |
| Quality (profitability) | Fundamental lens | 49 | 50 | 42 | 56th |
| Trend (momentum) | Fundamental lens | 54 | 50 | 69 | 54th |
The most recent call analysed was held on 2026-10-21 (fiscal 2026 Q3). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -9.5%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta 1.01, sector beta 0.07, industry beta 1.07; the factor model explains 67% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Illumina Inc. (ILMN) | 71.0 | B+ | +22.1% |
| Quest Diagnostics Incorporated (DGX) | 69.4 | B | -4.1% |
| Agilent Technologies Inc. (A) | 69.2 | B | -3.1% |
| Revvity Inc. (RVTY) | 69.2 | B | +8.2% |
| IQVIA Holdings Inc. (IQV) | 68.8 | B | -16.5% |
| Labcorp Holdings Inc. (LH) | 68.8 | B | -13.5% |
| Natera Inc. (NTRA) | 68.5 | B | -22.9% |
| Charles River Laboratories International Inc. (CRL) | 68.0 | B | -15.8% |
Danaher Corp. financial statements · Healthcare sector ranking · Diagnostics & Research industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.